Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies-Reference-Cited by-同舟云学术

Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies

Published:2024-08-08 Issue: Volume: Page:1-10
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Martino Enrica Antonia¹,Bruzzese Antonella¹,Labanca Caterina¹,Mendicino Francesco¹,Lucia Eugenio¹,Olivito Virginia¹,Stanzione Gaia¹²,Zimbo Annamaria¹³,Pozzi Stefano⁴,Neri Antonino⁵,Morabito Fortunato⁶,Vigna Ernesto¹,Gentile Massimo¹⁷

Affiliation:

1. Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy

2. Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Catania, Italy

3. UOC Laboratorio Analisi Cliniche, Biomolecolari e Genetica, Azienda Ospedaliera Annunziata, Cosenza, Italy

4. Ematologia Azienda USL-IRCSS Reggio Emilia, Reggio Emilia, Emilia-Romagna, Italy

5. Scientific Directorate IRCCS of Reggio Emilia, Reggio Emilia, EmiliaRomagna, Italy

6. Biotechnology Research Unit, AO of Cosenza, Cosenza, Italy

7. Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy

Funder

Progetto Ricerca Finalizzata

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2024.2388567

Reference134 articles.

1. Hematopoietic Recovery Following Induction Therapy of Acute Leukemias: Prognostic Implications and a New Look at the Definition of Remission

2. Microenvironmental niches in the bone marrow required for B-cell development

3. Regulation of hematopoiesis by the chemokine system

4. Chemokines, chemokine receptors and hematopoiesis

5. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia